# Retatrutide References: Full Citation List with DOIs and PubMed Links

> Complete reference list for all retatrutide claims on this site — Phase 1b, Phase 2, and review papers with DOIs and PubMed links.

Every citation used on this site — peer-reviewed journals, DOIs, PubMed IDs. Retatrutide references ordered by citation number.

## Full citation list

See the references index below. All quantitative claims on this site are cited to one of these 13 sources. PubMed links and DOIs are provided for independent verification. [Retatrutide references](/references) are numbered [1]–[13] consistently across all pages.

## References

[1] Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/
[2] Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. https://pubmed.ncbi.nlm.nih.gov/37385280/
[3] Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. https://pmc.ncbi.nlm.nih.gov/articles/PMC11255275/
[4] Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. https://pubmed.ncbi.nlm.nih.gov/36354040/
[5] Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. https://pmc.ncbi.nlm.nih.gov/articles/PMC11271400/
[6] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/
[7] Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers. Metabol Open. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11420505/
[8] Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist: a systematic review and meta-analysis. Proc (Bayl Univ Med Cent). 2025. https://pubmed.ncbi.nlm.nih.gov/40291085/
[9] Retatrutide showing promise in obesity (and type 2 diabetes). Expert Opin Investig Drugs. 2023. https://pubmed.ncbi.nlm.nih.gov/37947489/
[10] Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis. Diabetes Obes Metab. 2025. https://pubmed.ncbi.nlm.nih.gov/41090431/
[11] Coskun T, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a randomised, double-blind, placebo- and active-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2025. https://doi.org/10.1016/S2213-8587(25)00092-0
[12] Neumann J, et al. Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart. Pharmaceutics. 2026;18(4):447. https://doi.org/10.3390/pharmaceutics18040447
[13] Cooper ME, et al. GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. J Clin Invest. 2025;135(21):e194749. https://doi.org/10.1172/JCI194749

---

Trial data on one investigational compound — published, cited, and held by no clinic and no vendor.